Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

What happened

Vor Bio reported third quarter 2026 financial results and said it completed enrollment in its Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis, with topline results expected in the first half of 2027. It reported $481.6 million in cash and investments.

Confirmed

Global impact / market context

The $481.6 million cash balance is expected to fund operations into early 2029, which means the company likely avoids raising money soon. That matters because raising money later can dilute existing shareholders, while full enrollment moves the lead trial closer to a possible approval filing.

Analyst inference

Vor Bio is a clinical-stage biotechnology company, meaning it has no approved product revenue from these programs yet and depends on trial success. Investors typically weigh cash runway against trial risk, and the company is also running trials in ocular myasthenia gravis and primary Sjögren's disease.

Analyst inference

What to watch

1. Topline results from the Phase 3 UPSTREAM MG trial are expected in the first half of 2027, a key readout for telitacicept in generalized myasthenia gravis. Positive data could support a regulatory submission. Confirmed
2. The Phase 3 registrational UPSTREAM oMG trial in ocular myasthenia gravis plans its first patient dosing in the first half of 2027. Enrollment progress would show whether the expanded franchise stays on schedule. Proposed
3. Watch spending and enrollment in the ongoing Phase 3 UPSTREAM SjD trial in primary Sjögren's disease, because slower enrollment or higher costs could shorten the cash runway now expected to last into early 2029. Analyst inference

Evidence

• globenewswire.com